Javascript must be enabled to continue!
The Efficacy of Tamsulosin Monotherapy and Its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Hyperplasia
View through CrossRef
Abstract
Background
Alpha 1 adrenoceptor antagonists such as (tamsulosin) are developed for treating of overactive bladder (OAB) associated with benign prostatic hyperplasia (BPH), Acting by blockage of adrenoceptors so can cause relaxation of smooth muscle of the bladder neck and prostate, resulting in an improvement in urine flow and reduction in lower urinary tract symptoms (LUTS). Recently the beta-3 adrenoceptor agonist (mirabegron) has been shown to treat the(OAB) symptoms act by relaxation of detrusor smooth muscle of the bladder, increase the bladder capacity and minimize lower urinary tract symptoms (LUTS) that is associated with (BPH) with less side effect than other pharmacotherapies. We will study the efficacy and safety of this combination therapy.
Objective
To compare the efficacy and safety of the combination therapy mirabegron and tamsulosin versus tamsulosin monotherapy in case of overactive bladder associated with benign prostatic hyperplasia.
Material and method
this prospective randomized controlled study conducted in 60 patients between ages of 50-70years and complaining of lower urinary tract symptom(LUTS) associated with(BPH) benign prostatic hyperplasia, Before and 12 weeks after mirabegron additional therapy (50 mg once daily), we evaluated the efficacy of this treatment using the Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS), and changes in the maximum flow rate (Qmax) and post-void residual urine volume (PVR).
Results
60 men were enrolled in this study. The combination therapy improved the OABSS, IPSS total score and quality of life(QOL), the QMAX improved after treatment and there was no significant change in PVR.
Conclusions
Mirabegron add-on therapy was effective for male patients whose having LUTS particulary the OAB symptoms and storage symptoms that was not controlled by tamsulosin monotherapy with no effect on voiding function therefore the combination therapy considered effective more than monotherapy.
Oxford University Press (OUP)
Title: The Efficacy of Tamsulosin Monotherapy and Its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Hyperplasia
Description:
Abstract
Background
Alpha 1 adrenoceptor antagonists such as (tamsulosin) are developed for treating of overactive bladder (OAB) associated with benign prostatic hyperplasia (BPH), Acting by blockage of adrenoceptors so can cause relaxation of smooth muscle of the bladder neck and prostate, resulting in an improvement in urine flow and reduction in lower urinary tract symptoms (LUTS).
Recently the beta-3 adrenoceptor agonist (mirabegron) has been shown to treat the(OAB) symptoms act by relaxation of detrusor smooth muscle of the bladder, increase the bladder capacity and minimize lower urinary tract symptoms (LUTS) that is associated with (BPH) with less side effect than other pharmacotherapies.
We will study the efficacy and safety of this combination therapy.
Objective
To compare the efficacy and safety of the combination therapy mirabegron and tamsulosin versus tamsulosin monotherapy in case of overactive bladder associated with benign prostatic hyperplasia.
Material and method
this prospective randomized controlled study conducted in 60 patients between ages of 50-70years and complaining of lower urinary tract symptom(LUTS) associated with(BPH) benign prostatic hyperplasia, Before and 12 weeks after mirabegron additional therapy (50 mg once daily), we evaluated the efficacy of this treatment using the Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS), and changes in the maximum flow rate (Qmax) and post-void residual urine volume (PVR).
Results
60 men were enrolled in this study.
The combination therapy improved the OABSS, IPSS total score and quality of life(QOL), the QMAX improved after treatment and there was no significant change in PVR.
Conclusions
Mirabegron add-on therapy was effective for male patients whose having LUTS particulary the OAB symptoms and storage symptoms that was not controlled by tamsulosin monotherapy with no effect on voiding function therefore the combination therapy considered effective more than monotherapy.
Related Results
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
PROSTATIC HYPERPLASIA (BPH);
PROSTATIC HYPERPLASIA (BPH);
Objectives: To determine the efficacy of tamsulosin with and without tolterodine in patients having benign prostatic hyperplasia (BPH) with irritative (overactive bladder) symptoms...
Acupuncture combined with mirabegron is efficacious for the treatment of overactive bladder: a prospective randomized controlled trial
Acupuncture combined with mirabegron is efficacious for the treatment of overactive bladder: a prospective randomized controlled trial
Abstract
Purpose
To investigate the efficacy and safety of acupuncture combined with mirabegron for overactive bladder (O...
Effect of Electroacupuncture in Neurogenic Bladder: A Quasi-Experimental Study
Effect of Electroacupuncture in Neurogenic Bladder: A Quasi-Experimental Study
Neurogenic bladder (NB) is the dysfunction of either the urinary bladder, bladder neck or its sphincters due to diseases of the peripheral or central nervous system involved in the...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Outcome of Modification of Dose and Time of Administration of Tamsulosin in Men with Abnormal Ejaculation
Outcome of Modification of Dose and Time of Administration of Tamsulosin in Men with Abnormal Ejaculation
<b><i>Introduction:</i></b> Alpha-adrenergic blockers are now the cornerstone medication in management of lower urinary tract symptom (LUTS); however, the a...
Role of low-dose deflazacort with tamsulosin versus tamsulosin alone for medical expulsive therapy of ureteric stone
Role of low-dose deflazacort with tamsulosin versus tamsulosin alone for medical expulsive therapy of ureteric stone
Background: Urolithiasis is a common condition in daily urological practice. Medical Expulsive Therapy (MET) is non-invasive approach for removal of ureteric stone. In MET, alpha-b...

